{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wan KS"],"funding":["Kementerian Kesihatan Malaysia"],"pagination":["1922"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12804704"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) at the general population level in Malaysia is not known. This research aimed to determine the MALFD prevalence and the associated factors among adults in the country. The study utilised a cross-sectional study design with a two-stage stratified random sampling method across all states and federal territories in Malaysia. The data collection period was between July and September 2023, which included face-to-face interviews, clinical examinations, and venepuncture. MAFLD was defined as having a fatty liver (Fatty Liver Index of 60 or more) and the fulfillment of one or more of the three conditions: obesity or overweight, two or more abnormal metabolic risks, or having diabetes. There were 1,011 participants, and "],"journal":["Scientific reports"],"pubmed_title":["Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country."],"pmcid":["PMC12804704"],"funding_grant_id":["91000050"],"pubmed_authors":["Chan WK","Mohamad M","Mohd Noor N","Yoga Ratnam KK","Ahmad NA","Mohd Yusoff MF","Ganapathy SS","Wan KS","Abd Hamid HA","Mat Rifin H","Mustapha F"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country.","description":"The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) at the general population level in Malaysia is not known. This research aimed to determine the MALFD prevalence and the associated factors among adults in the country. The study utilised a cross-sectional study design with a two-stage stratified random sampling method across all states and federal territories in Malaysia. The data collection period was between July and September 2023, which included face-to-face interviews, clinical examinations, and venepuncture. MAFLD was defined as having a fatty liver (Fatty Liver Index of 60 or more) and the fulfillment of one or more of the three conditions: obesity or overweight, two or more abnormal metabolic risks, or having diabetes. There were 1,011 participants, and ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T13:49:35.013Z","creation":"2026-05-31T03:10:11.082Z"},"accession":"S-EPMC12804704","cross_references":{"pubmed":["41535699"],"doi":["10.1038/s41598-025-31737-0"]}}